Evidence mapPaperPMID 31395130Full record

ReviewJournal of the American College of Cardiology2019

Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel.

Victor J Del Brutto, Seemant Chaturvedi, Hans-Christoph Diener, Jose G Romano, Ralph L Sacco

Open access · greenAbstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Coexisting Dual Mechanisms of Ischaemic Stroke:Sultan Qaboos University medical journal · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Cerebrovascular Manifestations of SARS-CoV-2: A Comprehensive Review.Current treatment options in neurology · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Victor J Del BruttoDepartment of Neurology, University of Miami, Miller School of Medicine, Miami, Florida. Electronic address: vjdelbrutto@gmail.com.
Seemant ChaturvediDepartment of Neurology, University of Maryland, Baltimore, Maryland.
Hans-Christoph DienerInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Jose G RomanoDepartment of Neurology, University of Miami, Miller School of Medicine, Miami, Florida.
Ralph L SaccoDepartment of Neurology, University of Miami, Miller School of Medicine, Miami, Florida. Electronic address: rsacco@med.miami.edu.
University of Miami · USUniversity of Duisburg-Essen · DEUniversity of Maryland, Baltimore · US

Funding

Florida Regional Coordinating Center for the NINDS Stroke Trials NetworkU24NS107267 · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2025 to 2025
$364k
NINDS NIH HHS R01 NS084288NINDS NIH HHS U24 NS107267
6 · The paper itself

Abstract

Stroke survivors carry a high risk of recurrence. Antithrombotic medications are paramount for secondary prevention and thus crucial to reduce the overall stroke burden. Appropriate antithrombotic agent selection should be based on the best understanding of the physiopathological mechanism that led to the initial ischemic injury. Antiplatelet therapy is preferred for lesions characterized by atherosclerosis and endothelial injury, whereas anticoagulant agents are favored for cardiogenic embolism and highly thrombophilic conditions. Large randomized controlled trials have provided new data to support recommendations for the evidence-based use of antiplatelet agents and anticoagulant agents after stroke. In this review, the authors cover recent trials that have altered clinical practice, cite systematic reviews and meta-analyses, review evidence-based recommendations based on older landmark trials, and indicate where there are still evidence-gaps and new trials being conducted.

Indexed as

Fibrinolytic AgentsHumansIschemic Attack, TransientRecurrenceSecondary PreventionStrokeFibrinolytic Agentsanticoagulantsantiplateletsantithromboticsischemic strokesecondary prevention

Identifiers

PMID31395130
PMCPMC7291776
OpenAlexW2964508099

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.